China SXT Pharmaceuticals Inc logo

China SXT Pharmaceuticals Inc(SXTC)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$3
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SXTC

11/13/2026: SXTC (1-star) is currently NOT-A-BUY. Pass it for now.

China SXT Pharmaceuticals Inc is a micro-cap specialty pharmaceutical company that processes and sells traditional Chinese medicine pieces in China. While the firm benefits from an established operational footprint and participation in the growing traditional healthcare sector, it struggles with a sharply contracting revenue base, net losses, and heavy reliance on dilutive equity financing. Its primary growth challenge involves overcoming structural disadvantages against larger competitors, while key risks include high price volatility, intense market competition, and financial distress. The stock is suited primarily for speculative or momentum-oriented traders willing to accept high risk, requiring close monitoring of cash burn, regulatory compliance, and capital-structure events.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitRevenue contraction and shrinking business scale conflict directly with growth investment criteria.
Momentum investorStrong fit while signal remains positiveMicro-cap volatility and technical oversold bounces can occasionally attract short-term momentum traders.
Value investorWeak fitOngoing net losses and negative cash flows undermine traditional valuation arguments despite low absolute market capitalization.
Dividend investorWeak fitThe company does not pay dividends and retains all capital to fund ongoing operations.
Low-risk investorWeak fitHigh share price volatility, dilution risks, and financial distress indicators make this an unsuitable asset for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow float dynamics and micro-cap status cause extreme intraday and historical price swings.
Valuation riskMedium / highDisconnect between fundamental business size and market pricing creates unpredictable valuation risks.
Competition risk (traditional medicine processors and regional suppliers)High Intense rivalry from well-capitalized national and regional TCM competitors pressures market share.
Business qualityHighPersistently shrinking revenues and unprofitability highlight fundamental business model vulnerabilities.
Dividend incomeLow / noneNo dividend payouts are available or anticipated for income-seeking investors.
Execution riskHighManagement faces steep challenges in reversing top-line declines and optimizing cost structures.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 0.31M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 486.6K shares
Beta 2.01
52 Weeks Range 2.71 - 1000000.00
Updated Date 11/15/2026
52 Weeks Range 2.71 - 1000000.00
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -73040

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.7%
Active BUY / eligible
69 / 110
30-Day BUY Count Change
+30
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -9.42%
Avg. Invested days 22
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SXTC receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft company fundamentals, and soft quantitative characteristics.

Company Fundamentals

★★★★★
SXTC has soft overall fundamentals (2 stars), with soft financial health, weak growth momentum, and moderate ownership. In FY2026 versus FY2025, growth and ownership metrics are mixed: negative earnings growth (-87.8%), weak cash generation (FCF margin -374.5%), negative revenue growth (-38.4%).

Financial Health Rating

★★★★★
SXTC's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 86.8%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
SXTC's growth profile is soft, with the least-weak measure being revenue growth at -38.4% FY2026 versus FY2025. By comparison, while earnings growth (-87.8%, negative) and free-cash-flow growth (-71.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 0.0% (soft) and 258.9% of outstanding shares are publicly tradable (strong). Insider ownership of 2.26% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Royal Bank of Canada 0.00%
Caitong International Asset Management Co., Limited. 0.00%
UBS Group AG 0.00%
Sabby Management LLC 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
SXTC generates approximately $171 of gross profit, $-6,641 of operating income, and $-3,745 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -2.15% (Tax Credit)

Quantitative Style Profile

★★★★★
SXTC has a liquid profile. Elevated volatility is the primary drawback.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Traditional Chinese Medicine Pieces (TCMP)Manufacture and sale of Advanced, Fine, and Regular processed herbal pieces to hospitals, clinics, and distributors in China.This is the core revenue stream, though sales volumes have contracted sharply in recent periods.
TCM Homologous Supplements (TCMHS)Commercialization of dual-purpose health food and supplement items.Represents an ancillary wellness product line intended to capture consumer supplement demand.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value -26.74M
Price to Sales(TTM) 0.27
Enterprise Value -26.74M
Price to Sales(TTM) 0.27
Enterprise Value to Revenue 43.06
Enterprise Value to EBITDA 7.08
Shares Outstanding 103.58K
Shares Floating 268.20K
Shares Outstanding 103.58K
Shares Floating 268.20K
Percent Insiders 2.26
Percent Institutions 0.03

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.